Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2021-11-15 Regulatory Filings
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
110年第3季海外子公司投資
Regulatory Filings Classification · 95% confidence The document is a tabular disclosure of investment holdings and related financial figures for a company named 杏輝 (Xinghui). It includes details such as investment amounts, shareholding percentages, and recognized investment gains or losses for the third quarter of the 110th year (Taiwan calendar, corresponding to 2021). The document is short (1070 characters) and appears to be a regulatory disclosure of investment information rather than a full financial report. There is no indication that this is an annual or interim report, audit report, or earnings release. It is also not a meeting announcement, voting result, or management change. The content fits best as a regulatory filing providing investment information disclosures to a public information platform. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-11-15 Chinese
110年第3季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investments made by a Taiwanese listed company (杏輝) into mainland China, including capital amounts, investment methods, and recognized investment gains or losses. It includes notes explaining the investment methods, accounting bases for investment gains, and regulatory limits. The document is relatively short (1501 characters) and focuses on investment details rather than financial results or management commentary. It does not present a full financial report, earnings release, or management discussion. Instead, it appears to be a regulatory disclosure related to cross-border investments, likely required by a regulatory authority for transparency. Such disclosures typically fall under Regulatory Filings (RNS) as they do not constitute full reports or announcements of meetings, dividends, or capital changes.
2021-11-15 Chinese
110年第3季財務報告書 — 202104_1734_AI3.pdf
Regulatory Filings
2021-11-15 Chinese
110年第3季財務報告書 — 202104_1734_AI1.pdf
Regulatory Filings
2021-11-15 Chinese
110年第3季財務報告書 — 202103_1734_AI1.pdf
Regulatory Filings
2021-11-15 Chinese
110年第3季財務報告書 — 202102_1734_AI1.pdf
Regulatory Filings
2021-11-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.